BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
2 Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016;50:418-26. [PMID: 27904450 DOI: 10.1515/raon-2015-0045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
3 Agnello F, Salvaggio G, Cabibbo G, Maida M, Lagalla R, Midiri M, Brancatelli G. Imaging appearance of treated hepatocellular carcinoma. World J Hepatol 2013; 5(8): 417-424 [PMID: 24023980 DOI: 10.4254/wjh.v5.i8.417] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
4 Cabibbo G, Tremosini S, Galati G, Mazza G, Gadaleta-Caldarola G, Lombardi G, Antonucci M, Sacco R. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014;14:831-845. [PMID: 24850249 DOI: 10.1586/14737140.2014.920694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
5 Koga F, Kobayashi S, Fujii Y, Ishioka J, Yokoyama M, Nakanishi Y, Matsuoka Y, Numao N, Saito K, Masuda H, Kihara K. Significance of Positive Urine Cytology on Progression and Cancer-Specific Mortality of Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2014;12:e87-93. [DOI: 10.1016/j.clgc.2013.07.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
6 Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, Marinelli S, Benevento F, Golfieri R, Bolondi L. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liver Dis. 2014;46:549-555. [PMID: 24630947 DOI: 10.1016/j.dld.2014.02.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
7 Henry JC, Malhotra L, Khabiri H, Guy G, Michaels A, Hanje J, Azevedo M, Bloomston M, Schmidt CR. Best radiological response to trans-arterial chemoembolization for hepatocellular carcinoma does not imply better outcomes. HPB (Oxford) 2013;15:196-202. [PMID: 23374360 DOI: 10.1111/j.1477-2574.2012.00529.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
8 Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golfieri R. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729-736. [PMID: 26604044 DOI: 10.1111/liv.13029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
9 Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, Kudo M, Pirisi M, Sharma R. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015;13:1204-8.e2. [PMID: 25528009 DOI: 10.1016/j.cgh.2014.11.037] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
10 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 27.0] [Reference Citation Analysis]
11 Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. Semin Oncol 2014;41:406-14. [PMID: 25023357 DOI: 10.1053/j.seminoncol.2014.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
12 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
13 Cabibbo G, Maida M, Cammà C, Craxì A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Rev Anticancer Ther. 2013;13:1355-1361. [PMID: 24224926 DOI: 10.1586/14737140.2013.859989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
14 Cabibbo G, Maida M, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxì A, Cammà C. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016. [PMID: 23922893 DOI: 10.1371/journal.pone.0070016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
15 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Cabibbo G, Reig M, Gadaleta-caldarola G, Galati G, Lombardi G, Mazza G, Marzi L, Saitta C, Nault J, Sacco R. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1. Future Oncology 2016;12:281-4. [DOI: 10.2217/fon.15.323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 2012; 4(9): 256-261 [PMID: 23060970 DOI: 10.4254/wjh.v4.i9.256] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
19 Makramalla A, Itri JN, Choe KA, Ristagno RL. Transarterial Therapies for Hepatocellular Carcinoma. Seminars in Roentgenology 2016;51:95-105. [DOI: 10.1053/j.ro.2016.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, Han CJ, Park SC, Kim SB, Kim YH. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016;11:22. [PMID: 26896371 DOI: 10.1186/s13014-016-0597-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
21 Han JW, Yoon SK. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics 2021;13:1387. [PMID: 34575463 DOI: 10.3390/pharmaceutics13091387] [Reference Citation Analysis]
22 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 9.7] [Reference Citation Analysis]
23 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Huo TI. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther. 2012;36:551-559. [PMID: 22817677 DOI: 10.1111/j.1365-2036.2012.05226.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
24 Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20:3779-3786. [PMID: 23846786 DOI: 10.1245/s10434-013-3127-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 113] [Article Influence: 9.3] [Reference Citation Analysis]
25 Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumour Biol 2014;35:11473-81. [PMID: 25123269 DOI: 10.1007/s13277-014-2478-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
26 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: A review of literature. World J Gastroenterol 2014; 20(15): 4141-4150 [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
27 Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol 2018; 24(15): 1641-1649 [PMID: 29686471 DOI: 10.3748/wjg.v24.i15.1641] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
28 Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2014;40:1270-81. [DOI: 10.1111/apt.12992] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
29 Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Translational Research 2012;160:146-52. [DOI: 10.1016/j.trsl.2012.01.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
30 Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, Santis AD, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology 2018;17:110-8. [DOI: 10.5604/01.3001.0010.7542] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
31 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
32 Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 2013;17:2123-32. [PMID: 24065364 DOI: 10.1007/s11605-013-2348-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
33 Hsu C, Liu P, Lee Y, Hsia C, Huang Y, Chiou Y, Tsai Y, Nagaria TS, Huo T. Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. Ann Surg Oncol 2015;22:1324-31. [DOI: 10.1245/s10434-014-4151-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
34 Saito M, Seo Y, Yano Y, Momose K, Hirano H, Yoshida M, Azuma T. Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. PLoS One 2013;8:e55441. [PMID: 23520445 DOI: 10.1371/journal.pone.0055441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
35 Hyder O, Dodson RM, Nathan H, Herman JM, Cosgrove D, Kamel I, Geschwind JF, Pawlik TM. Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg 2013;217:896-906. [PMID: 24041557 DOI: 10.1016/j.jamcollsurg.2013.07.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
36 Chu HH, Kim JH, Shim JH, Gwon DI, Ko HK, Shin JH, Ko GY, Yoon HK, Kim N. Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2830. [PMID: 34204125 DOI: 10.3390/cancers13112830] [Reference Citation Analysis]
37 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
38 Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Goo DE, Park SY. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Gut Liver 2017;11:409-16. [PMID: 28208001 DOI: 10.5009/gnl16001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
39 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
40 Barman PM, Sharma P, Krishnamurthy V, Willatt J, McCurdy H, Moseley RH, Su GL. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci. 2014;59:2821-2825. [PMID: 24973040 DOI: 10.1007/s10620-014-3247-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
41 Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma. 2019;6:105-117. [PMID: 31372364 DOI: 10.2147/jhc.s168682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]